Physician profile
Amanda Keeton
NPI 1093530552
$1,432.51
in general payments reported to CMS, 2019-2025
25 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379 · Education: $53.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.14 |
| Education | $53.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.33 | 2025 | |
| Phathom Pharmaceuticals, INC. | $127.56 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $110.97 | 2025 | Jynarque, Rexulti |
| Verona Pharma, INC. | $101.77 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $82.11 | 2025 | Mounjaro, Jardiance, Zepbound |
| Argenx US, INC. | $75.09 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $73.11 | 2025 | Andembry |
| Vanda Pharmaceuticals INC. | $72.74 | 2025 | Hetlioz, Fanapt |
| Dexcom, INC. | $68.52 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $53.86 | 2025 | Cologuard Collection Kit |
| Opko Pharmaceuticals, LLC | $53.37 | 2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $49.28 | 2025 | |
| Aimmune Therapeutics, INC. | $43.71 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $41.10 | 2025 | Farxiga, Airsupra |
| Viatris Specialty LLC | $38.75 | 2025 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $38.23 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $37.11 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.88 | 2025 | Xifaxan |
| Corcept Therapeutics | $31.06 | 2025 | Korlym |
| Travere Therapeutics, INC. | $30.60 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.91 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.53 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $20.13 | 2025 | Verquvo |
| Novo Nordisk INC | $19.14 | 2025 | Ozempic |
| Axsome Therapeutics, INC. | $16.65 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Keeton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.